登录 注册 会员服务 联系我们

Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity

  • Published:2024-02-28 Issue:4 Volume:70 Page:571-573
  • ISSN:0009-9147
  • Container-title:Clinical Chemistry
  • language:en
  • Short-container-title:

Author:

von Itzstein Mitchell S12,Gerber David E123ORCID

Affiliation:

1. Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center , Dallas, TX , United States

2. Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX , United States

3. Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center , Dallas, TX , United States

Publisher

Oxford University Press (OUP)

Reference15 articles.

1. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer;Drilon;N Engl J Med,2024

2. Mechanisms of resistance to tyrosine kinase inhibitors in ROS1 fusion-positive nonsmall cell lung cancer;Zhao,2024

3. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer;Song;Clin Cancer Res,2015

4. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition;Lin;NPJ Precis Oncol,2020

5. How lung cancer cells change identity;von Itzstein;Elife,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3